AI-generated analysis. Always verify with the original filing.
MapLight Therapeutics reported Q4 and full year 2025 financial results with net loss of $79.5 million and $161.2 million respectively, cash position of $453.1 million funding through 2027, and provided pipeline updates including Phase 2 topline results expected in Q3 2026 for ML-007C-MA in schizophrenia and ML-004 in ASD.
Event Type
Disclosure
Mandatory
Variant
8-K
, and Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or ot
, and Exhibit 99.2 hereto, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated March 26, 2026 99.2 Corporate Presentation, dated March 26,